Amicus Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDAmicus Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 92), indicating clear outperformance against the broad market. Earnings growth of 379% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $14.32 | +0.36% | ABOVE |
| 50 SMA | $14.16 | +1.48% | ABOVE |
| 100 SMA | $11.69 | +22.96% | ABOVE |
| 150 SMA | $10.31 | +39.41% | ABOVE |
| 200 SMA | $9.25 | +55.35% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is FOLD in an uptrend right now?
FOLD has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, FOLD is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is FOLD overbought or oversold?
FOLD's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is FOLD outperforming the market?
FOLD has a Relative Strength (RS) Rating of 92 out of 99. Yes, FOLD is a market leader, outperforming 92% of all stocks over the past 12 months.
Where is FOLD in its 52-week range?
FOLD is trading at $14.37, which is 100% of its 52-week high ($14.38) and 100% above its 52-week low ($5.51).
How volatile is FOLD?
FOLD has a Beta of 0.65 and 52-week volatility of 49%. It's less volatile than the S&P 500 - generally more stable.